Lazard Asset Management
ATRA icon

Lazard Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Lazard Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-368
Closed -$2K – 2295
2025
Q1 		$2K Sell
368
-76
-17% -$663 ﹤0.01% 2200
2024
Q4 		$5K Buy
444
+315
+244% +$3.32K ﹤0.01% 2128
2024
Q3 		$1K Sell
129
-179
-58% -$1.53K ﹤0.01% 2120
2024
Q2 		$2K Buy
+308
New +$4.63K ﹤0.01% 2097
2023
Q4 		– Sell
-285
Closed -$10K – 2248
2023
Q3 		$10K Buy
285
+14
+5% +$623 ﹤0.01% 2140
2023
Q2 		$10K Buy
271
+99
+58% +$5.6K ﹤0.01% 2180
2023
Q1 		$12K Sell
172
-443
-72% -$43K ﹤0.01% 2110
2022
Q4 		$50K Buy
615
+138
+29% +$14.4K ﹤0.01% 1810
2022
Q3 		$45K Buy
+477
New +$53.6K ﹤0.01% 1832
2021
Q2 		– Sell
-5
Closed -$1K – 1957
2021
Q1 		$1K Hold
5
– – ﹤0.01% 1821
2020
Q4 		$2K Buy
+5
New +$2.31K ﹤0.01% 1801

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lazard Asset Management's ATRA Position: Q2 2025 in Review

Lazard Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2025, closing a stake of 368 shares — an estimated $2K sold.

Lazard Asset Management first reported a position in ATRA in Q4 2020 and held it in 11 quarters. The position peaked at $50K in Q4 2022. 32 funds tracked by Wall St. Rank hold ATRA as of Q2 2025.

  • Lazard Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 368 Atara Biotherapeutics shares in Q2 2025, an estimated $2K.
  • Lazard Asset Management first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 11 quarters.
  • Lazard Asset Management's Atara Biotherapeutics position peaked at $50K in Q4 2022.
  • 32 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.